Company
Glycomine
The Missing Piece For Rare Genetic Diseases
Also known as Glycomine, Inc.
- Status
- Operatingas of 2026-09-17
- Business model
- B2B
- Legal name
- Glycomine, Inc.
- glycomine.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- X (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
Glycomine is developing replacement therapies for rare genetic diseases with the goal of delivering meaningful improvements in quality of life for patients, caregivers, and families.
Funding snapshot
- Total raised
- $115MSum of rounds, as of 2026-09-17Source (opens in a new tab)
- Latest round
- Series C, $115M2025-04-16
Funding rounds
- Series C
- $115M2025-04-16, Company stated
- Round, 2016
- $4.9M2016-10-27, SEC form D sold, 15 investors
Products
- Other
- GLM101
Loading relationship preview